Global Trends of Antimicrobial Susceptibility of Ceftaroline and Ceftazidime-Avibactam: A Surveillance Study from the ATLAS Program (2012-2016)

Abstract

Background: Antibiotic resistance is a global health threat.This study reported the global trends of antimicrobial susceptibility ofceftaroline and ceftazidime-avibactam using data from the Antimicrobial Testing Leadership And Surveillance (ATLAS)programbetween2012and2016.Methods:Theminimum inhibitory concentrations (MICs) andin vitro susceptibilities of ceftarolineandceftazidime-avibactam were assessed using the Clinical andLaboratory Standards Institute (CLSI) guidelines.Results:Between 2012 and 2016, a total of 176,345 isolates were collected globally and included for analysis.Regarding Gram-negative bacteria, ceftazidime-avibactam demonstrated high susceptibility (>90%) against EnterobacteriaceaeandPseudomonas aeruginosa, with increasedantimicrobial activity observed from the addition of avibactam (4 mg/L) to ceftazidime.Regarding Gram-positive bacteria, ceftaroline showed >90% susceptibility againstStaphylococcus aureus, Streptococcus pneumoniae, α-and β-hemolytic Streptococcus.The antimicrobial susceptibility of ceftaroline and ceftazidime-avibactam were mostly stable from 2012 to 2016. Nevertheless, the susceptibility ofceftazidime-avibactam to carbapenem-resistant Klebsiella pneumoniae(CRKPN, 88.4% to 81.6%) and to CR-Pseudomonas aeruginosa(CRPAE, 89.6% to 72.7%) decreased. In terms of regional difference, susceptibilities of MRSA to ceftaroline in Asia and of CRKPN to ceftazidime-avibactam in Asia/Africa-Middle East were loweras compared with other regions whereas the susceptibility of CRPAE to ceftazidime-avibactam in North America was higher.Conclusion: The addition of avibactam improved the activity of ceftazidime against EnterobacteriaceaeandPseudomonas aeruginosa. The global antimicrobial susceptibilities of ceftaroline and ceftazidime-avibactam were in general stable from 2012 to 2016, but a marked reduction in the susceptibility of CRPAEtoceftazidime-avibactam was observed.

Assessment of In vitro Activities of Ceftaroline, Ceftazidime/ avibactam and Colistin against different Gram Negative and Gram Positive Isolates

“…They are widely accessible all around the world. Resistance patterns to ceftazidime-avibactam, Colistin and Ceftaroline throughout the world are still to be characterized since they are essential data for tracking and assessing public health risks 6 .…”

In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections

“…11,12 This fifth-generation broad spectrum cephalosporin possesses activity against common Gram-positive pathogens found in bacterial skin and skin structure infections and community-acquired pneumonia, including MRSA. 13,14 Additionally, ceftaroline demonstrates activity against respiratory tract Gram-negative pathogens, including Moraxella catarrhalis, Haemophilus parainfluenzae and H. influenzae , along with other enteric bacilli. 15 Efficacy against β-lactam–resistant S. aureus can be explained by the high affinity of ceftaroline for staphylococcal PBPs 1, 2 and 3 and MRSA PBP2a.…”